Effects of macrolides and ketolides on mycobacterial infections

Current Pharmaceutical Design

Volumn 10, Issue 26, 2004, Pages 3221-3228

  Bermudez, Luiz E ^a   Yamazaki, Yoshitaka ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 733; AMIKACIN; AMINOSALICYLIC ACID; AZITHROMYCIN; CEFAZOLIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DAPSONE; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; ETHAMBUTOL; ETHIONAMIDE; HMR 3004; ISONIAZID; KANAMYCIN; KETOLIDE; MACROLIDE; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; ROXITHROMYCIN; TELITHROMYCIN; TEMAFLOXACIN; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ATYPICAL MYCOBACTERIOSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENTIATION; GASTROINTESTINAL DISEASE; HUMAN; IN VITRO STUDY; LEPROSY; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUBERCULOSIS;

ANIMALS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; KETOLIDES; MACROLIDES; MYCOBACTERIUM INFECTIONS; RANDOMIZED CONTROLLED TRIALS;

EID: 4644278171     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383241     Document Type: Review

References (78)

1. Bermudez L, Inderlied CB, Kolonoski P, Petrofsky M, Young LS. Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 1994; 38: 2717-21.
2. Inderlied CB, Young LS, and Yamada JK. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother 1987; 31: 1697-702.
3. Tomioka H. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648. Arch Immunol Ther Exp (Warsz) 2000; 48: 183-8.
4. Inderlied CB. Antimycobacterial agents: In vitro susceptibility testing, spectrum of activity, mechanisms of action and resistance, and assays for activity in biological fluids. In Lorian V (ed.), Antibiotics in Laboratory Medicine, 3rd ed. Williams & Wilkins, Baltimore, 1994.
5. Biehle J, Cavalieri SJ. In vitro susceptibility of Mycobacterium kansasii to clarithromycin. Antimicrob Agents Chemother 1992; 36: 2039-41.
6. Frieden TR, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276: 1229-35.
7. Dye C, Scheele S, Dolin P, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-86.
8. Espinal MA, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Eng J Med 2001; 344: 1294-303.
9. Gorzynski EA, Gutman SI, Allen W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother 1989; 33: 591-2.
10. Cavalieri SJ, Biehle JR, Sanders WE Jr. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 1542-5.
11. Klemens SP, et al. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob Agents Chemother 1993; 37: 2344-7.
12. Klemens SP, DeStefano MS, Cynamon MH. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1992; 36: 2413-7.
13. Watt B, Rayner A, Harris G. Comparative activity of azithromycin against clinical isolates of mycobacteria. J Antimicrob Chemother 1996; 38: 539-42.
14. Luna-Herrera J, Reddy VM, Daneluzzi D, Gangadharam PRJ. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995; 39: 2692-5.
15. Truffot-Pernot C, Lounis N, Grosset JH, Ji B. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2827-8.
16. Mor N, Esfandiari A. Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother 1997; 41: 2035-6.
17. World Health Organization Leprosy Unit. Risk of relapse in leprosy. World Health Organization document WHO/CTD/LEP/94.1. World Health Organization, Genova. 1994.
18. Franzblau SG, Hastings C. In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother 1988; 32: 1758-62.
19. Ji B, Jamet P, Perani EG, Bobin P, Grosset JH. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis 1993; 168: 188-90.
20. Shepard CC. The experimental disease that follows the injection of human leprosy bacillus into foot pads of mice. J Exp Med 1960; 112:445-54.
21. Baker RJ. The need for new drugs in the treatment and control of leprosy. Int J Lepr 1990; 58: 78-97.
22. Gelber RH. Progress in the chemotherapy of leprosy: status, issues and projects. Prog Drug Res (Basel) 1990; 34: 421-45.
23. Gelber RH. The killing of Mycobacterium leprae in mice by various dietary concentrations of dapsone and rifampicin. Lepr Rev 1986; 57: 347-464.
24. Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swanson RN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989; 33: 1531-4.
25. Cynamon MH, Klemens SP. Activity of azithromycin against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 1992; 36: 1611-3.
26. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrobial Agents Chemother 1991; 35: 462-70.
27. Yajko DM, Sanders CA, Madej JJ, Cawthon VL, Hadley WK. In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium. Antimicrob Agents Chemother 1996 40:743-9.
28. Klemens SP, DeStefano MS, Cynamon MH. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1992; 36: 2413-7.
29. Cynamon MH, Klemens SP. Activity of azithromycin against Mycobacterium avium infection in beige mice. Antimicrobial Agents Chemother 1992; 36: 1611-3.
30. Mor N, Vanderkolk J, Mezo N, Heifets L. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium. Antimicrob Agents Chemother 1994; 38: 2738-42.
31. Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolates from patients with disseminated disease. Antimicrob Agents Chemother 1995; 39: 2625-2630.
32. Meier A, et al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994; 38: 381-384.
33. Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrobial Agents Chemother 1993; 37: 2364-2370.
34. Chaisson RE, et al. AIDS clinical trials group. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121: 905-11.
35. Bermudez LE, Petrofsky M, Kolonoski P, Young LS. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. Antimicrobial Agents Chemother 1998; 42: 180-3.
36. Nash K. Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. Antimicrobial Agents Chemother 2001; 45: 1607-14.
37. Chin DP, et al. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients--a prospective study. J Infect Dis 1994; 170: 578-84.
38. Horsburgh CR Jr, Gettings J, Alexander LN, Lennox JL. Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000. Clin Infect Dis 2001; 33: 1938-43.
39. Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 1332-8.
40. Dautzenberg B, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis 1991; 144: 564-9.
41. Chaisson RE, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team Ann Intern Med 1994; 121: 905-11.
42. Shafran SD, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 1996; 335: 377-83.
43. Gordin FN, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999; 28: 1080-5.
44. Cohn DL, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 1999; 29: 125-33.
45. Young LS, et al. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 1991; 338: 1107-9.
46. Koletar SL, et al. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. Antimicrob Agents Chemother 1999; 43: 2869-72.
47. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. N Engl J Med 1993; 329: 898-904.
48. Kovacs J, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342: 1416-29.
49. Benson CA, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000; 181: 1289-97.
50. Pierce M, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384-91.
51. Havlir DV, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group N Engl J Med 1996; 335: 392-8.
52. Rosenzweig DY. Pulmonary mycobacterial infections due to Mvcobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest 1979; 75: 115-9.
53. Prince DS, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321: 863-8.
54. Wallace RJ Jr, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994; 149: 1335-41.
55. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest 1995; 107: 1035-40.
56. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996; 153: 1766-72.
57. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156: S1-S25.
58. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160: 866-72.
59. Griffith DE, Brown BA, Cegieiski P, Murphy DT, Wallace RJ Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000; 30: 288-92.
60. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 983-9.
61. Griffith DE, et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001; 32: 1547-53.
62. Bermudez LE, Wu M, Young LS. Clarithromycin at a subinhibitory concentration inhibits Mycobacterium avium biofilm formation. (Abst) ICMAS Meeting, Bologna, Italy. 2002.
63. Wallace RJ, Swenson JM, Silcox VA, Bullen MG. Treatment of non-pulmonary infection due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985; 152: 500-14.
64. Griffith DE, Girard WM, Wallace RJ. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-8.
65. Agouridas C, Bonnefoy A, Chantot JF. Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens. Antimicrob Agents Chemother 1997; 41: 2149-58.
66. Bermudez LE, Inderlied CB, Kolonoski P, Wu M, Young LS. Activity of HMR 3004 against Mycobacterium avium complex in the beige mouse model. Clin Microbiol Infect 1998; 4: 325-31.
67. Bermudez LE, et al. Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment.Antimicrob Agents Chemother 2001; 45: 2210-4.
68. Cynamon MH, Carter JL, Shoen CM. Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 2000; 44: 2895-2896.
69. Rastogi N, Goh KS, Berchel M, Bryskier A. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobcteria at pHs 6.8 and 7.4. Antimicrobiol Agents Chemother 2000; 44: 2848-52.
70. Vazifeh DH, Abdelghaffar H, Labro MT. Cellular accumulation of the new ketolides RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob Agents Chemother 1998; 41: 2099-107.
71. Vaziheh D, Preira A, Bryskier A, Labro MT. Interations between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 1998; 42: 1944-51.
72. Meier A, et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 1996; 174: 354-60.
73. Wallace RJ Jr, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996; 40: 1676-81.
74. Dunne M, et al. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 2000; 31: 1245-52.
75. Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, et al. AIDS Clinical Trials Group 223 Protocol Team. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37: 1234-43.
76. Farina C, Gagliardi S. Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharm Design 2002; 8(23): 2033-48.
77. Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease. Curr Pharm Design 2002; 8(6): 441-54.
78. Yanagihara K. Design of anti-bacteria drug and anti-mycobacterial drug for drug delivery system. Curr Pharm Design 2002; 8(6): 475-82.